December Warning Letters Addressed API Testing and Microbial Control
This article was originally published in The Gold Sheet
Executive Summary
Analytical shortfalls at active pharmaceutical ingredient manufacturers around the world figured prominently in the nine drug cGMP warning letters that FDA’s center for drugs posted online in December.